Skip to main content
. 2020 Jan 23;3(1):148–160. doi: 10.1021/acsptsci.9b00085

Figure 6.

Figure 6

Perifosine synergizes with vincristine in a MYCN-amplified xenografted neuroblastoma model. (A, B) Perifosine was administered by oral gavage 5 days/week throughout the study, and vincristine was administered by i.v. once daily for the first 5 days. Kaplan–Meier survival curves (n = 8/group) of BE(2)-C (A) or SK-N-AS (B) tumor-grafted mice treated by vehicle (black), perifosine alone (blue), vincristine alone (red), or their combination (orange). (C) Tumors were collected after 1 week of treatment, and tumor size was determined in the different groups in nude mice harboring MYCN-amplified BE(2)-C xenograft tumors (n = 4/group; Student’s t-test; *, p < 0.05). (D) Western blot analysis in protein extracts from BE(2)-C xenografted cells after 1 week of treatment of vehicle (black), perifosine 20 mg/kg (oral gavage, daily, blue), vincristine 0.2 mg/kg (i.v. 5 days, red), and the combination vincristine with perifosine (orange). n = 3 different mice/group. Blots were probed with the indicated antibodies. GAPDH was used as a loading control.